Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Rubinstein
Larry V
LV
Dancey
Janet E
JE
Korn
Edward L
EL
Smith
Malcolm A
MA
Wright
John J
JJ
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D018450:Disease Progression; D018572:Disease-Free Survival; D023381:Endpoint Determination / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design; D018401:Sample Size; D016896:Treatment Outcome
D000970:Antineoplastic Agents